Infographic | April 21, 2025

Antibody-Drug Conjugates: Manufacturing Precision Medicines

Source: Cytiva
Antibody-Drug Conjugates: Manufacturing Precision Medicines

The monoclonal antibody (mAb) intermediate is meticulously designed and produced to possess the specific characteristics necessary for effectively receiving the linker-payload complex and ensuring its precise delivery to the intended target. This process involves rigorous engineering to achieve the desired attributes, which are critical for the successful conjugation and functionality of the final product. To preserve these essential attributes, stringent measures are implemented during storage and transportation. The mAb intermediate is stored under controlled conditions that prevent degradation or alteration of its properties.

Examine why these precautions are vital to maintaining the quality and efficacy of the mAb intermediate to ensure that it performs optimally in subsequent stages of the conjugation process.

access the Infographic!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online